Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on July 28, 2019. The report details a strategic expansion into the women's health sector through its subsidiary, Mayfield Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses on a material definitive agreement rather than periodic financial performance.
Material Changes and Agreements
On July 28, 2019, Mayfield Pharmaceuticals, Inc. entered into a License Agreement (the "TGV License") with TGV-Health, LLC and TGV-Gyneconix, LLC. Key terms include:
- Acquisition: Intellectual property rights for use in the women's health field related to Mayfield's proprietary drug candidate MAY-66.
- Equity Consideration: Mayfield issued 300,000 shares of its common stock to TGV.
- Royalties: Mayfield is obligated to pay TGV a low single-digit percentage of net sales from products based on the licensed intellectual property.
- Milestones: Mayfield is required to make certain milestone payments over the development of MAY-66 and related products.
- Cooperation: TGV agreed to assist in transferring know-how and protecting patent rights.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a corporate presentation used by management at investor conferences. The document contains forward-looking statements regarding the transaction. Management highlighted the following risks and contingencies:
- Potential delays or failure of the transaction to close.
- Difficulties with the integration process or realizing expected benefits.
- General regulatory developments impacting compounding pharmacies, outsourcing facilities, and the pharmaceutical industry.
Investor Verification Checklist
- Verify the exact terms of the milestone payments and the specific "low single-digit" royalty percentage in the full TGV License agreement.
- Review the attached Exhibit 99.1 (Mayfield Pharmaceuticals Corporate Presentation) for additional context on the MAY-66 drug candidate.
- Assess the impact of the 300,000 share issuance on Mayfield's capital structure and potential dilution.
- Monitor regulatory updates regarding compounding pharmacies and outsourcing facilities that could affect the commercialization of MAY-66.